Global Sepsis Diagnostics Market Size, Share, and COVID-19 Impact Analysis, By Product (Blood Culture Media, Software), By Technology (Microbiology, Molecular Diagnostics, Immunoassays, and Others), By Method (Automated Diagnostics and Conventional Diagnostics), By Pathogen (Bacterial, Fungal, and Others), By End User (Hospitals and Specialty Clinics, Pathology & Reference Laboratories, Research Laboratories & Academic Institutes), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 – 2032

Industry: Healthcare


Global Sepsis Diagnostics Market Insights Forecasts to 2032

  • The Global Sepsis Diagnostics Market Size was valued at USD 685.4 million in 2022.
  • The market is growing at a CAGR of 9.3% from 2022 to 2032.
  • The worldwide Sepsis Diagnostics Market size is expected to reach USD 1675.85 million by 2032.
  • Asia Pacific is expected to grow the fastest during the forecast period.


Sepsis Diagnostics Market

Get more details on this report -

Request Free Sample PDF

The Global Sepsis Diagnostics Market Size is expected to reach USD 1675.85 million by 2032, at a CAGR of 9.3% during the forecast period 2022 to 2032.


Market Overview

When the body's reaction to infection results in tissue damage, sepsis, a potentially lethal illness, occurs. Organs operate irregularly and inefficiently when the body's defenses against illness turn against them. Septic shock is a possible outcome of sepsis. Organ failure and death may result from this extreme reduction in blood pressure. To diagnose sepsis, the infection must be proven by symptoms such as altered mental state, systolic blood pressure, and respiration rate. Sepsis typically affects patients who are in or have recently been out of the hospital. Infections that might cause sepsis are more common in patients in intensive care units. A blood test is not sufficient to detect sepsis; other lab tests are needed. Analyses of blood samples look for indications of infections, clotting issues, abnormal liver or kidney function, reduced oxygen availability, and electrolyte abnormalities. The critical care unit of a hospital is where sepsis patients need to be closely monitored and treated. The stabilization of respiratory and cardiac function may necessitate life-saving treatments.


Report Coverage

This research report categorizes the global sepsis diagnostics market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global sepsis diagnostics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global sepsis diagnostics market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.


Global Sepsis Diagnostics Market Report Coverage

Report CoverageDetails
Base Year:2022
Market Size in 2022:USD 685.4 million
Forecast Period:2022 - 2032
Forecast Period 2022 - 2032 CAGR:9.3%
2032 Value Projection:USD 1675.85 million
Historical Data for:2018 - 2021
No. of Pages:210
Tables, Charts & Figures:125
Segments covered:By Product, By Technology, By Method, By Pathogen, By End User, By Region
Companies Covered:bioMérieux SA, Becton, Dickinson and Company, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, Danaher Corporation (Beckman Coulter, Inc.), Luminex Corp., Bruker Corp., Cepheid, Bruker Corporation, Immunexpress, Inc., Koninklijke Philips N.V.

Get more details on this report -

Request Free Sample PDF

Driving Factors

The global incidence has grown exponentially during the previous few decades. Any infection can lead to this illness, which sets off a series of events that results in organ failure and tissue destruction. For instance, 1.7 million persons in the United States will have sepsis in 2021, and about 270,000 will die as a result, according to a study by the National Institute of General Medical Sciences. There was a high demand for efficient diagnostic tools due to factors including the rise in these instances. Also, the increasing cost of healthcare, which helps to develop its infrastructure, is a crucial element affecting the market's growth rate for sepsis diagnostics. Moreover, the ability to diagnose sepsis has been significantly improved by technological breakthroughs. Sepsis-causing bacteria and biomarkers may be quickly and accurately detected utilizing newer diagnostic platforms including molecular diagnostics, multiplex assays, and point-of-care testing tools. Sepsis diagnoses have become more sensitive, specific, and effective with the development of automated blood culture methods, next-generation sequencing, and sophisticated immunoassays.


Restraining Factors

Blood culture tests can cost as less as USD 28–35, but molecular diagnostic tests might cost anywhere between USD 300 and USD 3,000, according to the National Institutes of Health. Between the two test kinds, this indicates a sizable pricing disparity. Public hospitals and academic research laboratories lack the financial resources required to purchase such systems; despite the existence of companies whose main focus is the development of computer-aided diagnostic instruments for detecting sepsis using cutting-edge technologies like sepsis molecular diagnostics. It is also increasingly proving to be a substantial roadblock to the expansion of the market for sepsis diagnosis tools.


Market Segmentation

  • In 2022 the blood culture media product segment is influencing the market with the largest market share during the forecast period.

Based on products, the global sepsis diagnostics market is segmented into blood culture media and software. Among these segments, the blood culture media product segment is dominating the market with the largest revenue share during the forecast period. This is because blood cultures are regarded by doctors as the most practical and economical testing strategy. Also, due to the rise in the elderly population, rise in the number of sepsis cases, high incidence of bloodstream infection, rise in the demand for quick diagnostic methods, and high frequency of infectious illnesses.


  • In 2022, the microbiology technology segment is dominating the largest market growth over the forecast period.

Based on the technology, the global sepsis diagnostics market is classified into microbiology, molecular diagnostics, immunoassays, and others. Throughout these segments, the microbiology technology segment is dominating the market. This is because microbiology technology enables precise detection and identification of bacteria for sepsis diagnosis through the use of culture media assays. The category expansion is also being fueled by fresh strategic efforts taken by important companies.


  • In 2022, the automated segment is leading the largest market share during the forecast period.

On the basis of the method, the global sepsis diagnostics market is divided into automated diagnostics and conventional diagnostics. Among these segments, the automated segment is dominating the market with the largest share during the forecast period. Based on agreed criteria that have been used to automate the detection of sepsis, billing codes, and predictable evaluation have been implemented. Even though billing codes are simple to extract and have a high positive predictive value (PPV) for sepsis, they frequently do not record the beginning of sepsis. In comparison to physician assessment, they are less sensitive. They are also impacted by evolving healthcare practices and payment schemes. Over time and between institutions, consensus-based definitions have become better. The poor PPV when automated is because physicians must still confirm whether organ failure is caused by sepsis.


  • In 2022, the hospitals and specialty clinics segment is dominating the market with the largest market share during the forecast period.

On the basis of end users, the global sepsis diagnostics market is segmented into hospitals and specialty clinics, pathology & reference laboratories, research laboratories & academic institutes. Among these segments, the hospitals and specialty clinics segment is dominating the market with the largest revenue share during the forecast period. This is because there are more patients with sepsis, and hospitals and clinics do numerous blood culture tests to identify bloodstream infections (BSIs) brought on by bacteria, fungi/yeast, or viruses.


Regional Segment Analysis of the sepsis diagnostics market

  • North America (U.S., Canada, Mexico) 
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Rest of APAC)
  • South America (Brazil and the Rest of South America) 
  • The Middle East and Africa (UAE, South Africa, Rest of MEA)


North America dominates the market with the largest market share during the forecast period


Sepsis Diagnostics Market

Get more details on this report -

Request Free Sample PDF

North America is dominating the significant market growth during the forecast period due to the area is anticipated to maintain its dominance. This expansion can be attributed to an established healthcare system that has made it simpler for locals to access more sophisticated diagnostic tools. The market is expanding in this area in part due to the strong presence of significant competitors and a reliable reimbursement system. Additionally, there will certainly be a greater demand for novel diagnostic techniques due to the prevalence of infectious disorders and sepsis. The market expansion is also being aided by the region's strong major player presence and a favorable reimbursement structure. Furthermore, it's anticipated that the rising prevalence of infectious disorders and sepsis would increase the need for cutting-edge diagnostic methods.


Asia Pacific is expected the second fastest-growing region during the forecast period

Asia Pacific is expected to grow at the highest growth rate over the forecast period due to the market for sepsis diagnostics expanding slowly because of a shortage of highly qualified laboratory personnel in expanding Asia-Pacific areas. The market in this area has been reenergized, nonetheless, by the rising number of new product approvals and launches. Healthcare costs in the Asia Pacific, except Japan (APEJ), are rising as a result of the region's growing population and improving living standards. The developing market for septic diagnostic services in these areas has thus been presented with huge prospects.


Competitive Analysis

The report offers the appropriate analysis of the key organizations/companies involved within the global sepsis diagnostics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.


List of Key Companies

  • bioMérieux SA
  • Becton, Dickinson and Company
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche AG
  • Danaher Corporation (Beckman Coulter, Inc.)
  • Luminex Corp.
  • Bruker Corp.
  • Cepheid
  • Bruker Corporation
  • Immunexpress, Inc.
  • Koninklijke Philips N.V.


Key Target Audience

  • Market Players
  • Investors
  • End-users
  • Government Authorities 
  • Consulting And Research Firm
  • Venture capitalists
  • Value-Added Resellers (VARs)


Recent Development

  • In May 2022, Health Canada has given the BIOFIRE Blood Culture Identification 2 (BCID2) Panel to bioMérieux SA. It is a quick molecular test for bloodstream infection.


  • In April 2022, Belgium authorized the Grand Pharmaceutical Group's STC3141 (a worldwide new medication for the treatment of sepsis) to carry out a phase Ib clinical trial.


  • In March 2022, The National Institutes of Health (NIH) provided funds to Dascena to carry out a clinical experiment to assess the precision and dependability of their HindSight algorithm in foretelling the start of sepsis in patients.


Market Segment

This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the Global Sepsis Diagnostics Market based on the below-mentioned segments:


Global Sepsis Diagnostics Market, By Product

  • Blood Culture Media
  • Software


Global Sepsis Diagnostics Market, By Technology

  • Microbiology
  • Molecular Diagnostics
  • Immunoassays
  • Others


Global Sepsis Diagnostics Market, By Method

  • Automated Diagnostics
  • Conventional Diagnostics


Global Sepsis Diagnostics Market, By Pathogen

  • Bacterial
  • Fungal
  • Others


Global Sepsis Diagnostics Market, By End Users

  • Hospitals and Specialty Clinics
  • Pathology & Reference Laboratories
  • Research Laboratories
  • Academic Institutes


Sepsis Diagnostics Market, By Regional Analysis

  • North America
    • US
    • Canada
    • Mexico 
  • Europe
    • Germany
    • Uk
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of the Middle East & Africa

Need help to buy this report?

Inquiry Before Buy
We'll use cookies to improve and customize your experience if you continue to browse. Is it OK if we also use cookies to show you personalized ads?
Learn more and manage your cookies
Yes, Accept Cookies